AB
KALV

Amalgamated Bank’s KalVista Pharmaceuticals KALV Stock Holding History

Amalgamated Bank’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,205
Closed -$19K – 2238
2025
Q4 		$19K Sell
1,205
-138
-10% -$1.83K ﹤0.01% 2130
2025
Q3 		$16K Hold
1,343
– – ﹤0.01% 2236
2025
Q2 		$15K Hold
1,343
– – ﹤0.01% 2239
2025
Q1 		$15K Buy
1,343
+278
+26% +$2.84K ﹤0.01% 2181
2024
Q4 		$9K Hold
1,065
– – ﹤0.01% 2482
2024
Q3 		$12K Hold
1,065
– – ﹤0.01% 2361
2024
Q2 		$13K Hold
1,065
– – ﹤0.01% 2307
2024
Q1 		$13K Sell
1,065
-1,028
-49% -$13.7K ﹤0.01% 2322
2023
Q4 		$26K Sell
2,093
-231
-10% -$2.1K ﹤0.01% 2532
2023
Q3 		$22K Hold
2,324
– – ﹤0.01% 2614
2023
Q2 		$21K Sell
2,324
-112
-5% -$1.03K ﹤0.01% 2714
2023
Q1 		$19K Sell
2,436
-568
-19% -$4.24K ﹤0.01% 2668
2022
Q4 		$20K Hold
3,004
– – ﹤0.01% 2750
2022
Q3 		$44K Hold
3,004
– – ﹤0.01% 2519
2022
Q2 		$30K Sell
3,004
-648
-18% -$7.15K ﹤0.01% 2718
2022
Q1 		$54K Buy
+3,652
New +$52.5K ﹤0.01% 2444

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Amalgamated Bank's KALV Position: Q1 2026 in Review

Amalgamated Bank sold out of KalVista Pharmaceuticals (KALV) in Q1 2026, closing a stake of 1,205 shares — an estimated $19K sold.

Amalgamated Bank first reported a position in KALV in Q1 2022 and held it in 16 quarters. The position peaked at $54K in Q1 2022. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Amalgamated Bank reported no remaining KalVista Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 1,205 KalVista Pharmaceuticals shares in Q1 2026, an estimated $19K.
  • Amalgamated Bank first reported a position in KalVista Pharmaceuticals in Q1 2022 and held it in 16 quarters.
  • Amalgamated Bank's KalVista Pharmaceuticals position peaked at $54K in Q1 2022.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.